INTERLEUKIN-21 IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA WHO UNDERWENT SPLENECTOMY-Reference-Cited by-同舟云学术

INTERLEUKIN-21 IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA WHO UNDERWENT SPLENECTOMY

Published:2022-04-11 Issue: Volume: Page:
ISSN:1512-0392
Container-title:EXPERIMENTAL & CLINICAL MEDICINE GEORGIA
language:
Short-container-title:jecm

Author:

METREVELI SOPHIO,KVACHADZE IRINE,KIKODZE NINO,NANAVA NINO,CHIKOVANI TINATIN,JANIKASHVILI NONA

Abstract

Antiplatelet autoantibodies that are produced as a result of B and T lymphocyte interactions are regarded to have a cardinal role in the pathogenesis of immune thrombocytopenia (ITP). In numerous autoimmune disorders, interleukin-21 (IL-21) is suggested to play an important role in the B cell stimulation by follicular helper T (TFH) and the enhancement of autoantibody production. The present study aimed to explore the levels of IL-21 in ITP patients who did not respond to first line treatment and had splenectomy as a second line therapy. Control group was comprised by patients who underwent splenectomy for other reasons than autoimmune or malignant hematological pathologies. Our results showed no significant difference in plasma levels of IL-21 between ITP patients and controls. Nevertheless, our data have clinically and scientifically important value, further investigations, considering previous treatments, refined controls and other research limitations, are needed to understand the detailed role of IL-21 in ITP pathogenesis.

Publisher

Association For Science (Publications)

Reference31 articles.

1. W. Ghanima, B. Godeau, D. B. Cines, and J. B. Bussel, “How I treat immune thrombocytopenia: The choice between splenectomy or a medical therapy as a second-line treatment,” Blood, vol. 120, no. 5, pp. 960–969, 2012, doi: 10.1182/blood-2011-12-309153.

2. M. Michel et al., “Platelet autoantibodies and lupus-associated thrombocytopenia,” Br. J. Haematol., vol. 119, no. 2, pp. 354–358, 2002, doi: 10.1046/j.1365-2141.2002.03817.x.

3. M. Kuwana, J. Kaburaki, Y. Okazaki, H. Miyazaki, and Y. Ikeda, “Two types of autoantibody-mediated thrombocytopenia in patients with systemic lupus erythematosus,” Rheumatology, vol. 45, no. 7, pp. 851–854, 2006, doi: 10.1093/rheumatology/kel010.

4. D. Nugent, R. McMillan, J. L. Nichol, and S. J. Slichter, “Pathogenesis of chronic immune thrombocytopenia: Increased platelet destruction and/or decreased platelet production,” Br. J. Haematol., vol. 146, no. 6, pp. 585–596, 2009, doi: 10.1111/j.1365-2141.2009.07717.x.

5. L. J. Toltl and D. M. Arnold, “Pathophysiology and management of chronic immune thrombocytopenia: Focusing on what matters,” Br. J. Haematol., vol. 152, no. 1, pp. 52–60, 2011, doi: 10.1111/j.1365-2141.2010.08412.x.